The Trump Administration is relying mainly on administrative action to advance its prescription drug pricing agenda because it has not received much help from Congress, but the limitations of that approach are beginning to show.
US Drug Pricing Reforms Testing Limits Of Executive Action
Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.
More from Market Access
• By
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
• By
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
• By
As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.
More from In Vivo
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
• By
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.